As of 9:30 AM on the 28th, Samsung Biologics is trading at 819,000 KRW, down 3.53% from the previous day. The trading volume is 71,844 shares, which is about 11.2% of the previous day's volume. Samsung Biologics is known as the holding company for Samsung Group's bio business.
On January 27, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "2021 guidance: Full operation of Plants 1 and 2, near full operation of Plant 3, and focus on order activities for Plant 4 in 2021. Based on target utilization rates, sales growth in 2021 is expected to be 20%, and operating profit margin is expected to improve compared to 25% in 2020. Maintenance of Plant 1 in Q4 may affect Q1 2021 results. The utilization rate of Plant 3 is rising faster than planned due to shortened technology transfer periods. Expansion costs for Plant 4 will be higher for buildings and machinery than for personnel. The main catalyst for future stock price will be the order size for Plant 4." He set the target price for Samsung Biologics at 1,000,000 KRW.
Over the past five days, individual investors have net sold 282,612 shares of Samsung Biologics, while foreigners and institutions have net bought 250,752 shares and 52,820 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
